Form 4: Inovio Pharmaceuticals Director Jay Shepard Reports Stock Option and Restricted Stock Unit Grants

Director Jay Shepard reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals, granted under the 2023 Omnibus Incentive Plan.

Summary

• Jay Shepard, a director of Inovio Pharmaceuticals, filed a Form 4 on May 22, 2024, reporting transactions related to the company's stock.
• On May 21, 2024, Shepard acquired 2,917 stock options with an exercise price of $10.99, vesting 100% on May 21, 2025, and expiring on May 21, 2034.
• Additionally, Shepard acquired 2,167 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock, also vesting 100% on May 21, 2025.
• These grants were made under the 2023 Omnibus Incentive Plan, in accordance with the issuer's non-employee director compensation policy.
• Following these transactions, Shepard directly owns 2,917 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard director compensation practice. The grants align director interests with shareholders, which is generally viewed positively, but it's not a major event.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule (100% on May 21, 2025) encourages the director's continued service and contribution to the company's success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The grants align the director's interests with shareholders, potentially encouraging decisions that benefit the company's long-term value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates